Intraperitoneale Chemotherapie

  • J. Preiß

Zusammenfassung

Der Begleitaszites bei malignen Erkrankungen ist ein Problem, das eine starke Beeinträchtigung der Lebensqualität hervorrufen kann und dann eine Therapie obligat erforderlich macht. Ursache des Aszites ist eine Peritonealkarzinose — in der Regel mit dem Nachweis von malignen Zellen im Erguß — oder eine tumorbedingte Leberfunktionsstörung (venöse oder lymphatische Abflußstörung) ohne Tumorzellen. Eine Besonderheit ist der Chylaskos durch direkte Tumorarrosion der Cisterna chyli oder deren zu- oder abfließenden großen Lymphgefäße.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Dufour P, Bergerat JP, Barats JC et al. (1993) Intraperitoneal mitoxantron as consolidation treatment for patients with ovarian carcinoma in pathological complete remission. Cancer 73: 1865–1869CrossRefGoogle Scholar
  2. Guastalla JP, Vermorken JB, Wits JA et al. (1994) Phase II trial for intraperitoneal cisplatin plus intravenous sodium thiosulfat in advanced ovarian carcinoma patients with minimal residual disease after Cisplatin-based chemotherapy–a phase II study of the EORTC Gynecological Cancer Cooperative Group. Eur J Cancer 30A: 45–49CrossRefGoogle Scholar
  3. Howell SB Kirmani S, Mc Clay EF et al. (1991) Intraperitoneal cisplatin-based chemotherapy for ovarian carcinoma. Semin Oncol 18 [Suppl 3]: 5–10PubMedGoogle Scholar
  4. Link KH, Hepp G, Staib L et al. (1992) Intraperitoneale regionale Chemotherapie (IPRC) mit Mitoxantron. In: Heidemann E, Kaufmann M, Schmidt W (Hsg): Aktuelle Onkologie Bd 66–Neue Konzepte in der systemischen und lokoregionalen Therapie mit Novantron. Zuckschwerdt, München, S 18–32Google Scholar
  5. Los G, Mc Vie JG (1990) Experimental and clinical status of intraperitoneal chemotherapy. Eur J Cancer 26: 755–762PubMedCrossRefGoogle Scholar
  6. Malmström H, Rasmussen S, Simonsen E (1993) Intraperitoneal high-dose Cisplatin and Etoposid with systemic thiosulfat protection in second-line treatment of advanced ovarian cancer. Gynecol Oncol 49: 166–171PubMedCrossRefGoogle Scholar
  7. Markman M (1991) Intraperitoneal chemotherapy. Semin Oncol 18: 248–254PubMedGoogle Scholar
  8. Markman M, Reichman, B, Hakes T et al. (1992) Impact on survival defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancer. J Clin Oncol 10: 1479–1484PubMedGoogle Scholar
  9. Markman M, Hakes T, Reichman B (1991) Intraperitoneal cisplatin and cytarabin in the treatment of refractory or recurrent ovarian carcinoma. J Clin Oncol 9: 204–210PubMedGoogle Scholar
  10. Mc Clay EF, Howell SB (1992) Intraperitoneal therapy in the management of patients with ovarian cancer. Hematol-Oncol Clinics North Am 6: 915–926 ( 1992Google Scholar
  11. Nicoletto MO, Padrini R, Ferrazzi E et al. (1993) Phase I-II intraperitoneal mitoxantrone in advanced pretreated ovarian cancer. Eur J Cancer 29A: 12421248Google Scholar
  12. O’Dwyer PJ, LaCreta FP, Daugherty P et al. (1991) Phase I pharmacokinetic study of intraperitoneal Etoposide. Cancer Res 51: 2041–2046PubMedGoogle Scholar
  13. Piver MS, Lel SB, Marchetti DL et al. (1988) Surgically documented response to intraperitoneal cisplatinum, cytarabin and bleomycin after intravenous cisplatin-based chemotherapy in advanced ovarian adenocarcinoma. J Clin Oncol 6: 1679–1684PubMedGoogle Scholar
  14. Shugarbaker PH, Gianola FJ, Speyer JL et al. (1985) Prospective randomized trial of intravenous v intraperitoneal 5-FU in patients with advanced primary colon or rectal cancer. Semin Oncol 12: 101–111Google Scholar
  15. Walton LA, Blessing JA, Homsley HD (1989) Adverse effects of intraperitoneal fluorouracil in patients with optimal residual ovarian cancer after second look laparotomy: a Gynecologic Oncology Group Study. J Clin Oncol 4: 466–470Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1997

Authors and Affiliations

  • J. Preiß

There are no affiliations available

Personalised recommendations